KIM
REGN icon

Kestra Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kestra Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$635 – 875
2025
Q2 		$635 Hold
1
– – ﹤0.01% 957
2025
Q1 		$635 Sell
1
-1,259
-100% -$866K ﹤0.01% 850
2024
Q4 		$898K Buy
1,260
+644
+105% +$540K 0.04% 153
2024
Q3 		$648K Buy
616
+200
+48% +$223K 0.03% 169
2024
Q2 		$437K Buy
+416
New +$403K 0.03% 88

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kestra Investment Management's REGN Position: Q3 2025 in Review

Kestra Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 1 share — an estimated $635 sold.

Kestra Investment Management first reported a position in REGN in Q2 2024 and held it in 5 quarters. The position peaked at $898K in Q4 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Kestra Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kestra Investment Management sold 1 Regeneron Pharmaceuticals share in Q3 2025, an estimated $635.
  • Kestra Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Kestra Investment Management's Regeneron Pharmaceuticals position peaked at $898K in Q4 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Kestra Investment Management's 13F filing for Q3 2025, filed 17 Nov 2025.